Rheumatology

Preclinical Data Supporting Tolerability and Activity of Low-dose Infigratinib in Treating Achondroplasia Presented at ASHG 2019 Annual Meeting

QED Therapeutics, Inc. and parent company BridgeBio Pharma, Inc announced the presentation of preclinical data supporting the potential of low-dose infigratinib for the treatment of achondroplasia. The data were presented during the ASHG 2019 Annual Meeting in a poster entitled "Low dose, daily or intermittent administration of infigratinib (BGJ398), a selective...